HER3 induction and activation have since been confirmed in independent, matched BM cohorts from breast and lung cancers, and unmatched BM from a wide range of primary cancer types, suggesting this is an adaptation of carcinoma cells to the neuregulin-rich microenvironment [29,73,107,108]. This evidence concerns the gene ERBB3 and lung cancer.